| 7/13/2010 | CVLM | OSI sets expiration on purchase offer for 2% convertibles at July 30; holders convert all 3% notes
|
| 6/18/2010 | CV | OSI 2% notes now convertible through July 19 on another major change
|
| 6/9/2010 | CV | OSI 2% notes are convertible through July 8 due to fundamental change
|
| 6/4/2010 | CV | OSI 2% notes remain convertible through July due to fundamental change
|
| 5/18/2010 | CV | Market Commentary: Convertibles quiet amid market uncertainty; Massey Energy steady to higher on lower shares
|
| 5/17/2010 | CV | Market Commentary: OSI takeout protection falls short on 3% convertibles; GLG jumps on takeout; Sybase steady
|
| 5/6/2010 | CVLM | OSI holders convert nearly all 3.25% convertibles ahead of redemption
|
| 4/1/2010 | CV | OSI Pharmaceuticals' 2% senior notes now convertible through June 30
|
| 3/22/2010 | CV | OSI Pharmaceuticals calls its remaining 3.25% convertibles due 2023
|
| 3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
| 3/1/2010 | CV | Market Commentary: Millipore a little weaker dollar neutral, but OSI Pharma expands; Amylin, Isis also in trade
|
| 12/22/2009 | CV | OSI buys back $79.5 million of convertibles for $75 million to date
|
| 7/23/2009 | CV | Market Commentary: Earnings help convertibles extend strength; Ford gains on profit; OSI, Human Genome higher
|
| 4/22/2009 | CV | Market Commentary: Watson, OSI add on buyout rumors; Alexandria up; Ford jumps, GM mixed; Old Republic to price
|
| 4/3/2009 | CV | OSI Pharmaceuticals 2% notes are convertible through June 30
|
| 12/4/2008 | CV | Market Commentary: Prudential longer paper gains; ImClone weaker; Advanced Micro mostly quiet on lowered outlook
|
| 10/1/2008 | CV | OSI Pharmaceuticals says 2% notes will remain convertible in fourth quarter
|
| 7/3/2008 | CV | OSI's 2% notes due 2025 are convertible
|
| 5/8/2008 | CV | OSI Pharmaceuticals buys back $37.9 million 3.25% convertibles
|
| 4/4/2008 | CV | OSI holders may convert 2% notes through second quarter
|
| 1/15/2008 | CV | OSI Pharmaceuticals greenshoe exercised in full, lifts 3% convertibles due 2038 to $200 million
|
| 1/8/2008 | CV | OSI Pharmaceuticals notes will be convertible through first quarter
|
| 1/4/2008 | CV | Market Commentary: Sallie slammed, drags down financials; Intel panned; drags down chips; OSI opens strong
|
| 1/4/2008 | CV | New Issue: OSI Pharmaceuticals prices upsized $175 million 3% convertible notes, up 65%
|
| 1/3/2008 | CV | Market Commentary: OSI deal looks cheap; Superior up on new contract; Ford slips; Intel, AMD continue dive; market slows
|
| 1/3/2008 | CV | Market Commentary: OSI deal looks cheap; Superior up on new contract; Ford slips; Intel, AMD continue dive; market slows
|
| 1/2/2008 | CV | OSI Pharmaceuticals launches $150 million 30-year convertible notes; talked at 3%-3.5%, up 57.5%-62.5%
|
| 1/2/2008 | CV | Market Commentary: Investors get good look at Sallie Mae; Intel drags down chips; near record gold drives Newmont surge
|
| 1/2/2008 | CV | OSI Pharmaceuticals plans to repurchase 3.25% convertibles
|
| 7/10/2007 | CV | OSI Pharmaceuticals 2% notes to remain convertible
|
| 1/9/2007 | CV | OSI Pharmaceuticals 2% notes to remain convertible through first quarter
|
| 11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
| 11/7/2006 | BT | Merrill reiterates OSI at buy
|
| 11/6/2006 | BT | OSI Pharmaceuticals to exit eye disease business, reports third quarter total revenues up 118%
|
| 10/20/2006 | BTCV | OSI Pharmaceuticals says holders may convert 2% convertibles through Dec. 29
|
| 10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
| 10/17/2006 | BT | Merrill rates OSI at buy
|
| 10/9/2006 | BT | Merrill puts OSI at buy
|
| 9/21/2006 | BT | OSI starts phase 3 trial of Tarceva in non-small cell lung cancer
|
| 9/11/2006 | BT | OSI says details of diabetes/obesity partnership expected to be in place by year-end
|
| 9/11/2006 | BT | Market Commentary: Genentech falls on Avastin delay; Vertex pitches $300 million deal; OSI off 2%; Genitope loses 5%
|
| 8/8/2006 | BT | Merrill keeps OSI at buy
|
| 8/7/2006 | BT | OSI Pharmaceuticals second-quarter total revenues up 194% at $102 million
|
| 7/20/2006 | BT | Merrill reiterates OSI at buy
|
| 7/19/2006 | BT | OSI reiterated at buy
|
| 7/12/2006 | BT | OSI maintained at buy by Merrill
|
| 7/5/2006 | BT | Merrill reiterates OSI at buy
|
| 7/3/2006 | BT | Market Commentary: Encore cheered as it goes private on Blackstone buyout at a 36% premium; Siemens, Bayer up
|
| 6/27/2006 | BT | OSI at buy by Merrill
|
| 6/26/2006 | BT | OSI, Pfizer start phase 4 trial of Macugen for age-related macular degeneration
|
| 6/13/2006 | BT | Merrill keeps OSI at buy
|
| 6/12/2006 | BT | OSI's PSN9301 reduces blood glucose levels in type 2 diabetes in phase 2a study
|
| 6/5/2006 | BT | Genentech, OSI report Avastin plus Tarceva limits progression in non-small cell lung cancer
|
| 6/5/2006 | BT | Merrill puts OSI at buy
|
| 6/1/2006 | BT | OSI's Macugen maintained or improved vision in more than 90% of patients
|
| 6/1/2006 | BT | Merrill Lynch comments on DPP-IV
|
| 6/1/2006 | BT | Merrill Lynch maintains buy on OSI
|
| 5/31/2006 | BT | Merrill Lynch maintains buy on OSI
|
| 5/9/2006 | BT | Merrill maintains OSI at buy
|
| 5/4/2006 | BT | OSI Pharmaceuticals summarizes positive Macugen data at ophthalmology meeting
|
| 4/26/2006 | BT | Merrill maintains OSI at buy
|
| 4/17/2006 | BT | OSI Pharmaceuticals files NDA for Tarceva in Japan
|
| 4/13/2006 | BT | Merrill rates OSI at buy
|
| 3/13/2006 | BT | OSI kept at outperform by Bear Stearns
|
| 3/13/2006 | BT | Merrill reiterates OSI at buy
|
| 3/8/2006 | BT | OSI at buy by Merrill
|
| 3/7/2006 | BT | OSI Pharmaceuticals says revenue jumps to $174.2 million in 2005
|
| 3/1/2006 | BT | Merrill keeps OSIP at buy
|
| 2/28/2006 | BT | Merrill keeps OSI at buy
|
| 2/24/2006 | BT | OSI, Pfizer three-year trial data review shows Macugen safe
|
| 2/21/2006 | BT | OSI begins phase 2a trial for its glycogen phosphorylase inhibitor, PSN357
|
| 2/21/2006 | BT | Market Commentary: Alnylam up 10% on Novartis pact; OSI off; CuraGen clipped; Inspire comes in; Ista drops despite data
|
| 2/15/2006 | BT | OSI advances diabetes program with phase 1 study
|
| 2/6/2006 | BT | OSI makes corporate governance changes
|
| 2/6/2006 | BT | Merrill reiterates OSI at buy
|
| 2/6/2006 | BT | Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
|
| 2/6/2006 | CV | Market Commentary: Huntsman converts fall as sale dropped; Transocean rises on new contracts; JetBlue slides on worries
|
| 2/3/2006 | BT | Market Commentary: DOV rises; ImmunoGen tumbles; OccuLogix, TLC-Vision plunge; Sirna spikes; CryoCor crumbles
|
| 2/2/2006 | BT | Pfizer, OSI Pharmaceuticals' Macugen approved for treatment of macular degeneration in Europe
|
| 1/17/2006 | BT | OSI maintained by Merrill at buy
|
| 1/12/2006 | BT | Market Commentary: OSI punishment over Eyetech buy continues; NPS up; PDL plunges; Genta; Favrille, Illumina all higher
|
| 1/11/2006 | BT | OSI says Tarceva U.S. sales up 15% in fourth quarter
|
| 1/11/2006 | BT | PR, OSI collaborate to develop sustained-release Macugen for macular degeneration
|
| 1/11/2006 | BT | OSI maintained by Merrill at buy
|
| 1/11/2006 | BT | Market Commentary: PDL, OSI Pharma, Biogen dive; Altus IPO launches, Vertex eases; Novogen shelves Glycotex IPO
|
| 12/30/2005 | BTCV | OSI Pharmaceuticals underwriter exercises greenshoe, raising convertibles to $115 million
|
| 12/22/2005 | BT | OSI grants license for dipeptidyl peptidase IV inhibitors
|
| 12/22/2005 | BT | Merrill keeps OSI at buy rating
|
| 12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
| 12/16/2005 | CV | Market Commentary: OSI Pharmaceuticals new issue rises, but ON Semiconductor slips; Carnival lower on higher dividend fears
|
| 12/16/2005 | BTCV | New Issue: OSI Pharmaceuticals $100 million 20-year convertibles yield 2%, up 25%
|
| 12/15/2005 | CV | Market Commentary: ON Semi, OSI Pharma at bat; Entergy goes to 50.5 bid; Intel steady; Abgenix issues climb
|
| 12/15/2005 | BTCV | OSI Pharma prices $100 million 20-year convertibles talked to yield 2%, up 25%
|
| 12/15/2005 | BT | Market Commentary: OSI Pharma on deck; Oxigene off on steep discount; BioCryst slips on PIPE; Somaxon sinks on debut
|
| 12/14/2005 | BT | OSI: European regulators to issue updated label approval of Macugen for age-related macular degeneration
|
| 12/14/2005 | BKBT | OSI Pharmaceuticals to syndicate new $75 million revolver
|
| 12/14/2005 | CV | Market Commentary: Intel, Ceradyne trade higher; United Dominion re-offered; Entergy up in gray; OSI launches $100 million
|
| 12/14/2005 | BTCV | OSI Pharma $100 million 20-year convertibles talked to yield 1.75%-2.25%, up 20%-25%
|
| 12/8/2005 | BT | OSI's Prosidion says phase 2b results promising for PSN9301 to treat type 2 diabetes
|
| 12/8/2005 | BT | Merrill maintains OSI at buy
|
| 11/21/2005 | BT | OSI maintained by Merrill Lynch at buy
|
| 11/14/2005 | BT | OSI Pharmaceuticals completes acquisition of Eyetech
|
| 11/14/2005 | BT | Market Commentary: OSI, Eyetech tie knot; Genentech hits new high; SkyePharma soars on buyout interest; Onyx launches
|
| 11/11/2005 | BT | Market Commentary: OSI Pharma, Eyetech lower; Coley steady after big net loss; King Pharma, Pain extend moves
|
| 11/10/2005 | BT | Eyetech shareholders back acquisition by OSI Pharma; OSI to assess Genentech's Lucentis data
|
| 11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
| 11/2/2005 | BT | OSI, Genentech get FDA approval for Tarceva to treat pancreatic cancer
|
| 10/18/2005 | BT | Merrill Lynch lowers price target for OSI
|
| 10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
| 10/3/2005 | BT | Amylin sales looking up as Biogen may face downside, Merrill report says
|
| 9/26/2005 | BT | Market Commentary: Eye drug names viewed in mixed fashion; Ligand gains on hopes of sale; Endo plunges on secondary
|
| 9/21/2005 | BT | Market Commentary: Nektar, Cyberonics pitch converts; QLT spirals; Chiron players shift to 2.75s; Alkermes stumbles
|
| 9/14/2005 | BT | OSI Pharma kept by Bear Stearns at outperform
|
| 9/13/2005 | BT | OSI Pharma reiterated by Bear Stearns at outperform
|
| 9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
| 9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
| 9/8/2005 | BT | OSI Pharma estimates cut by Merrill Lynch
|
| 9/2/2005 | BT | OSI Pharmaceuticals board affirms approval of Eyetech acquisition
|
| 8/26/2005 | CV | Market Commentary: DOV Pharmaceutical convertibles tumble; Atherogenics adds; Agilent active on call news
|
| 8/23/2005 | BT | Market Commentary: Amylin stock, convertibles zoom on drug data; OSI rebounds; Merck credit finds buyers; Wyeth sold off
|
| 8/22/2005 | BT | Market Commentary: Alpharma gains on deal chatter; OSI plunges, Eyetech up on deal; QLT higher; Acambis slides
|
| 8/22/2005 | CV | Market Commentary: Convertibles of Northwest Airlines firm; OSI Pharma drops on acquisition; CP Ships lifts on offer
|
| 8/22/2005 | BT | OSI Pharma to fund $935 million Eyetech acquisition with 75% cash, 25% stock, sees profitability in 2006
|
| 8/22/2005 | BT | OSI Pharmaceuticals maintained at buy: Merrill
|
| 8/10/2005 | BT | OSI Pharma estimates raised by Merrill Lynch
|
| 7/28/2005 | BT | OSI Pharma reiterated by Merrill at buy
|
| 7/12/2005 | BT | Market Commentary: Planet Biotech targets VC funds; Rigel, Keryx decline; Genentech rises, pushes OSI Pharma higher
|
| 7/12/2005 | BT | OSI Pharma target raised by Merrill
|
| 7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
| 7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
| 7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|
| 7/19/2004 | CV | OSI holders convert all $160 million of 4% notes to 3.2 million shares
|
| 6/18/2004 | CV | Market Commentary: OSI Pharma 4% convertible falls 6 points on call; Delta soars on bets pilots cave, no bankruptcy
|
| 6/18/2004 | CV | OSI Pharmaceuticals calls $160 million of 4% convertibles
|
| 6/7/2004 | CV | Market Commentary: Mandalay event sparks furor on concern about no cash takeover protection; 20-30 names suffer
|
| 5/12/2004 | CV | Market Commentary: CV Therapeutics bid at 100.375 in gray market; Pixelworks still; OSI Pharma, ImClone up sharply
|
| 4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
| 4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
| 3/3/2004 | CV | Market Commentary: Disney little changed on concerns besides Eisner; PSS soars to 106; Toys up on hoped-for store sales
|
| 11/20/2003 | CV | Lehman prefers OSI Pharmaceuticals 3.25% convertibles over 4% converts on cheapness
|
| 9/4/2003 | CV | Market Commentary: Issuance seen slowing, with more classic small cap issuers; Gap plunges; techs mostly higher
|
| 9/3/2003 | CV | New Issue: OSI Pharmaceuticals $135 million convertibles yield 3.25%, up 32.5%
|
| 9/3/2003 | CV | Market Commentary: Rite Aid drops 3 points as Merrill pans stock; Openwave bid up in gray; OSI Pharmaceuticals dips
|
| 9/2/2003 | CV | OSI Pharmaceuticals launches $135 million convertible
|
| 9/2/2003 | CV | Market Commentary: Traders see activity pick up, largely in anticipation of new deals waiting in the wings
|
| 1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
| 9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
| 8/29/2002 | CV | OSI Pharmaceuticals buys back $40 million convertibles on "over-reaction"
|
| 8/22/2002 | CV | Wachovia analyst: Not all is lost for OSI Pharmaceuticals' drug prospect
|
| 8/20/2002 | CV | Market Commentary: New deals stimulate players; retailers find bargain hunters
|
| 8/19/2002 | CV | Market Commentary: OSI, ImClone wounded; retailers build on strong surge at Lowe's
|
| 7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
| 5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
| 5/14/2002 | CV | Market Commentary: Broadbased gains as better retail sales confirm recovery signs
|
| 1/30/2002 | CV | Market Commentary: Convertibles snap back somewhat but witch-hunt continues
|
| 1/29/2002 | CV | New Issue: OSI Pharmaceuticals upsized $200 million convertibles yield 4.0%, up 23.3%
|
| 1/29/2002 | CV | Market Commentary: Convertibles spiral sharply lower on witch-hunt for accounting flags
|
| 1/28/2002 | CV | Market Commentary: Convertibles market preps for new deals, telecoms sink on Global Crossing bankruptcy
|
| 1/25/2002 | CV | Market Commentary: Convertibles flat as braces for busy week ahead
|
| 1/24/2002 | CV | OSI Pharmaceuticals $150 million convertibles talked 4.0-4.5% yield, up 17.5-22.5%
|
| 1/24/2002 | CV | Market Commentary: Awaiting Ford terms, convertibles flat as market watched Greenspan, Enron hearings
|
